03:20 , May 6, 2017 |  BioCentury  |  Strategy

mDx blueprint

Thanks to a well-planned robust pivotal trial and a dose of good timing, Cologuard from Exact Sciences Corp. is enjoying one of the steepest launch trajectories of any molecular diagnostic. After 10 quarters of sales,...
07:00 , Jun 25, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer NDRG family member 4 (NDRG4) Studies in human tissues and in cell lines suggest that the tumor suppressor NDRG4 could be a marker...